Education
About Us
Working with TipRanks
Follow Us
Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
RESEARCH TOOLSreports
Total Valuation
Daito Pharmaceutical Co., Ltd. has a market cap or net worth of ¥32.53B. The enterprise value is ¥34.46B.
Market Cap¥32.53B
Enterprise Value¥34.46B
Share Statistics
Daito Pharmaceutical Co., Ltd. has 30,696,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding30,696,880
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Daito Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.76%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.76%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee43.83M
Profits Per Employee3.94M
Employee Count1,070
Asset Turnover0.60
Inventory Turnover1.77
Valuation Ratios
The current PE Ratio of Daito Pharmaceutical Co., Ltd. is 10.60. Daito Pharmaceutical Co., Ltd.’s PEG ratio is -0.36.
PE Ratio10.60
PS Ratio0.00
PB Ratio0.65
Price to Fair Value0.67
Price to FCF-23.63
Price to Operating Cash Flow7.97
PEG Ratio-0.36
Income Statement
In the last 12 months, Daito Pharmaceutical Co., Ltd. had revenue of 46.90B and earned 3.29B in profits. Earnings per share was 209.99.
Revenue46.90B
Gross Profit9.84B
Operating Income3.89B
Pretax Income4.22B
Net Income3.29B
EBITDA7.92B
Earnings Per Share (EPS)209.99
Cash Flow
In the last 12 months, operating cash flow was 1.84B and capital expenditures -4.89B, giving a free cash flow of -3.05B billion.
Operating Cash Flow1.84B
Free Cash Flow-3.05B
Free Cash Flow per Share-99.29
Dividends & Yields
Daito Pharmaceutical Co., Ltd. pays an annual dividend of ¥70, resulting in a dividend yield of 6.6%
Dividend Per Share¥70
Dividend Yield6.6%
Payout Ratio49.51%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.31
52-Week Price Change-3.63%
50-Day Moving Average1.02K
200-Day Moving Average1.04K
Relative Strength Index (RSI)55.64
Average Volume (3m)92.68K
Important Dates
Daito Pharmaceutical Co., Ltd. upcoming earnings date is Jul 11, 2025, TBA Not Confirmed.
Last Earnings DateApr 14, 2025
Next Earnings DateJul 11, 2025
Ex-Dividend DateMay 29, 2025
Financial Position
Daito Pharmaceutical Co., Ltd. as a current ratio of 2.24, with Debt / Equity ratio of 9.78%
Current Ratio2.24
Quick Ratio1.11
Debt to Market Cap0.19
Net Debt to EBITDA0.76
Interest Coverage Ratio94.98
Taxes
In the past 12 months, Daito Pharmaceutical Co., Ltd. has paid 1.04B in taxes.
Income Tax1.04B
Effective Tax Rate0.25
Enterprise Valuation
Daito Pharmaceutical Co., Ltd. EV to EBITDA ratio is 5.17, with an EV/FCF ratio of -37.40.
EV to Sales0.87
EV to EBITDA5.17
EV to Free Cash Flow-37.40
EV to Operating Cash Flow7.90
Balance Sheet
Daito Pharmaceutical Co., Ltd. has ¥3.24B in cash and marketable securities with ¥11.32B in debt, giving a net cash position of ¥8.08B billion.
Cash & Marketable Securities¥3.24B
Total Debt¥11.32B
Net Cash¥8.08B
Net Cash Per Share¥263.12
Tangible Book Value Per Share¥3.30K
Margins
Gross margin is 22.91%, with operating margin of 8.30%, and net profit margin of 7.03%.
Gross Margin22.91%
Operating Margin8.30%
Pretax Margin8.99%
Net Profit Margin7.03%
EBITDA Margin16.89%
EBIT Margin9.08%
Analyst Forecast
The average price target for Daito Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast8.07%
EPS Growth Forecast-45.20%